Earn Perry
Founder bij Musli Thyropeutics Ltd.
Profiel
Earn Perry is a managing director and founder of Maruho Israel Innovation Fund, which was founded in 2018.
He is also the founder of ICD Pharma Ltd., Musli Thyropeutics Ltd., and Upstream Bio, Inc. Currently, he holds the position of Director at MyBiotics Pharma Ltd.
Mr. Perry has an MBA from The Trustees of Columbia University in The City of New York and has completed undergraduate and graduate degrees from Tel-Aviv University.
Actieve functies van Earn Perry
| Bedrijven | Functie | Begin |
|---|---|---|
| Musli Thyropeutics Ltd. | Founder | - |
MyBiotics Pharma Ltd.
 MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | Director/Board Member | - |
Eerdere bekende functies van Earn Perry
| Bedrijven | Functie | Einde |
|---|---|---|
Maruho Israel Innovation Fund
 Maruho Israel Innovation Fund Financial ConglomeratesFinance Maruho Israel Innovation Fund engages in investments in dermatology-related technologies, biotech, medical devices, digital health, and cosmetics. The company was founded by Junichi Hamada, Eran Perry, Doron Friedman, and Masanobu Ogawa in 2018 and is headquartered in Rehovot, Israel. | Founder | - |
Upstream Bio, Inc.
 Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Founder | - |
| ICD Pharma Ltd. | Founder | - |
Opleiding van Earn Perry
| The Trustees of Columbia University in The City of New York | Masters Business Admin |
| Tel-Aviv University | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
MyBiotics Pharma Ltd.
MyBiotics Pharma Ltd. BiotechnologyHealth Technology MyBiotics Pharma Ltd. operates as a micro biome pharmaceutical company that develops live bacteria based drugs. It develops MyCrobe and SuperDonor technologies for growing specific bacterial communities on pre-selected particles for stable and resistant raw material and for multi bacterial products. The company was founded in and is headquartered in Ness Ziona, Israel. | Health Technology |
| Musli Thyropeutics Ltd. | |
Maruho Israel Innovation Fund
Maruho Israel Innovation Fund Financial ConglomeratesFinance Maruho Israel Innovation Fund engages in investments in dermatology-related technologies, biotech, medical devices, digital health, and cosmetics. The company was founded by Junichi Hamada, Eran Perry, Doron Friedman, and Masanobu Ogawa in 2018 and is headquartered in Rehovot, Israel. | Finance |
| ICD Pharma Ltd. | |
Upstream Bio, Inc.
Upstream Bio, Inc. Miscellaneous Commercial ServicesCommercial Services Upstream Bio, Inc. is a clinical-stage biopharmaceutical company based in Waltham, MA, USA. The American company's lead program, upb-101, is a monoclonal antibody that inhibits the TSLP receptor, a validated target that affects various immune cells involved in common and rare diseases. Upstream Bio is leveraging its diverse roots and substantial industry experience to develop therapies that ease the burden of inflammatory and allergic diseases on patients and their loved ones. The company was founded by Eran Perry and Earn Perry, and Samantha Truex has been the CEO since 2021. | Commercial Services |
